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Abstract
Background: Cow’s milk allergy (CMA) is one of the most prevalent human food-borne allergies, particularly in
infants and young children from developed countries. Our study aims to evaluate the effects of Lactobacillus
rhamnosus GG (LGG) administration on CMA development using whole cow’s milk proteins (CMP) sensitized Balb/C
mice by two different sensitization methods.
Methods: LGG supplemented mice were either sensitized orally with CMP and cholera toxin B-subunit (CTB) as
adjuvant, or intraperitoneally (IP) with CMP but without the adjuvant. Mice were then orally challenged with CMP
and allergic responses were accessed by monitoring hypersensitivity scores, measuring the levels of CMP-specific
immunoglobulins (IgG1, IgG2a and IgG) and total IgE from sera, and cytokines (IL-4 and IFN-g) from spleen lysates.
Results: Sensitization to CMP was successful only in IP sensitized mice, but not in orally sensitized mice with CMP
and CTB. Interestingly, LGG supplementation appeared to have reduced cow’s milk allergy (CMA) in the IP group of
mice, as indicated by lowered allergic responses.
Conclusions: Adjuvant-free IP sensitization with CMP was successful in inducing CMA in the Balb/C mice model.
LGG supplementation favourably modulated immune reactions by shifting Th2-dominated trends toward Th1-
dominated responses in CMP sensitized mice. Our results also suggest that oral sensitization by the co-
administration of CMP and CTB, as adjuvant, might not be appropriate to induce CMA in mice.
Background
Cow’s milk allergy (CMA), an immunologically mediated
reaction to cow’s milk proteins [1], is one of the most
prevalent human food-borne allergies, particularly in
infants and young children. In North America, incidence
of CMA is estimated at 2.5% in children and about 1%
in adults with a 75% outgrowing rate at 16 years of age
[2]. Milk protein comprises a mixture of multiple pro-
teins, including whey (such as b-lactoglobulin, a-lactal-
bumin and bovine serum albumin) and casein (such as
a-S1-, a-S2-, b-, -, and g-caseins) proteins. Hypersensi-
tivity reactions may occur upon exposure to a single or
multiple milk protein(s). Numerous attempts have been
made to reduce or eliminate the allergenicity of milk
proteins. Of these attempts, most have focussed on two
approaches: to alter the structure and property of milk
proteins through thermal treatments, biochemical pro-
cesses (enzymatic digestion), irradiation [3] and high
pressure treatments [4], and to modulate immune
responses through sensitization and tolerance induction
by means of controlled exposure to a specific allergen
which is commonly referred to as specific immunother-
apy [5]. Nevertheless, total avoidance of cow’sm i l ko r
its associated products still remains as the best remedy
for CMA. Hypersensitivity to orally ingested food
usually occurs upon failure to induce oral tolerance.
Research with germ-free mice has indicated that the
interaction between allergens and host’s gut microbiota
plays a crucial role in oral tolerance development [6]
and in reducing secretions of allergen-specific antibodies
[7]. The gut microbiota is also reported to favour anti-
allergenic reactions by mediating T-helper-1 (Th1) type
of immunity [8] or inducing IL-10 and transforming
growth factor-b (TGF-b)t h a ts u p p r e s s e sT - h e l p e r - 2
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exposure and/or reduced diversity of the gut microbiota
among children have been associated with higher allergy
incidences [10]. This concept was first reported by Stra-
chan [11] and later widely known as the ‘hygiene
hypothesis’. Interestingly, whereas the gut microbiota of
allergic infants contained higher levels of Clostridia,
intestinal Lactobacilli and Bifidobacteria were more pre-
dominant among healthy infants [12,13]. Such findings
have triggered considerable scientific interests in probio-
tics, particularly Lactobacilli and Bifidobacteria, for pre-
vention or treatment of allergies among infants. The
allergy reducing effects of probiotics against food aller-
gens such as egg ovalbumin [14,15] and whey proteins
[16] have been demonstrated in mouse allergy models.
But, to the best of our knowledge, probiotic effects of
Lactobacillus rhamnosus GG (LGG) to reduce or control
allergy to whole cow’s milk protein (CMP) have not yet
been reported in a mouse allergy model. We used the
Balb/C mice model based on its similarity with the
human immune system, particularly the Th1 and Th2
responses [17].
Oral sensitization is well recognized as an ideal route
to investigate allergic responses to food allergens.
Because mice usually develop oral tolerance and fail to
manifest allergic responses to ingested allergens, aller-
gens are frequently co-administered with an adjuvant.
However, recent reports indicate that commonly used
adjuvants, such as cholera toxin (CT) and alum, possess
immune-stimulatory properties that may falsely test
non-allergenic food products as positive [18]. Conse-
quently, there is increasing interest to develop adjuvant-
free systemic sensitization models for testing food aller-
genicity in mice. The main objectives of this study were
to evaluate probiotic effects of LGG on CMA develop-
ment in a Balb/C mouse model using either an adju-
vant-assisted oral sensitization (CMP with cholera toxin
B-subunit, CTB) method or an adjuvant-free systemic
sensitization (CMP only) method.
Materials and methods
Cow’s Milk Proteins
Cow’s milk proteins were prepared from fresh milk.
Briefly, milk was defatted by centrifuging at 1,000 g for
10 min at 4°C and discarding the upper fat layer [19].
After addition of 12% trichloroacetic acid (TCA) (w⁄v),
milk proteins were allowed to precipitate for 2 h at 4°C
before centrifuging at 9,300 g for 10 min at 4°C. The
supernatant was discarded and equal volume of distilled
water was added more than five times to the precipi-
tated whole milk protein to remove excess TCA. The
concentrated CMP was then lyophilized and stored at 4°
C. CMP’s protein content (82.34 ± 0.53%) was verified
by the Kjeldahl method whereas the presence of major
milk proteins was confirmed by 12% SDS-PAGE gel
electrophoresis.
Mice
Three weeks-old female Balb/C mice were purchased
from Charles River Breeding laboratories (St. Constant,
Quebec, Canada). All mice were fed a diet that was free
from animal proteins and microbes (Harlan Teklad,
Madison, WI, USA). Feed and water were provided ad
libitum. Mice were raised in individual cages, and under
a 12L:12D lighting cycle, 20-24°C range of ambient tem-
perature and 40-70% of relative humidity. The animal
use protocol was approved by the McGill University
Animal Care Committee.
Sensitization and Challenge Procedures
Intragastrically Sensitized (Gavage) Group
The experimental design for the CMP intragastrically
sensitized group is shown in Figure 1a. At 4 weeks of
age, mice were sub-divided into 5 experimental sub-
groups (n = 6/group) which included mice gavaged
with: PBS (CTL-), PBS + CTB [0.25 μg/g BW] (CTB),
a n dC M P[ 1m g / gB W ]+C T B( C T L + )i nat o t a l
volume of 200 μl at weekly intervals over 4 consecutive
weeks. The last 2 treatments, namely LGG1 and LGG2,
included mice from the CTL+ sub-group that were
orally treated with a viable dose of LGG (1 × 10
9
CFU/day) over 3 days per week. Mice in the LGG1
sub-group received their first LGG dose at 23 d which
lasted over 5 weeks whereas LGG2 received LGG from
31 d of age over 4 weeks. The LGG dosage was
adopted from a dose-response study with LGG strain
HN001 in mice [20]. Four weeks after the first sensiti-
zation, mice in all treatment groups were orally chal-
lenged with CMP as previously described [19] with
minor modifications. Briefly, mice were fasted over-
night and challenged with two doses of CMP (30 mg/
mouse) at 30 min interval. Two hours after the last
dose, mice were euthanized by carbon dioxide asphyx-
iation. Blood was collected by intracardiac puncture
and then spleens were aseptically excised and cryopre-
served for later cytokine analyses.
Intraperitoneally Sensitized (IP) Group
The experimental design for CMP intraperitoneally
sensitized group is shown in Figure 1b. There were 4
treatments in the IP group of mice which included
CTL-, CTL+, LGG1, and LGG2 similar to the gavage
group of mice. At 6 and 7 weeks of age, each mouse in
the 4 treatment groups received 2 doses of CMP (10
mg/mouse) dissolved in 250 μl of PBS intraperitone-
ally. One week after the second IP sensitization, mice
were orally challenged with CMP, and blood and
spleen samples were collected similar to mice of the
gavage group.
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Within an hour following the final oral CMP challenge,
hypersensitivity symptoms were scored by a person
blind to the study using the score system as described
by Schouten et al. [21]. The scores were as follows: 0 =
no symptom; 1 = scratching and rubbing around the
nose and head; 2 = reduced activity; 3 = activity after
prodding and puffiness around the eyes and mouth; 4 =
no activity after prodding, laboured respiration, and cya-
nosis around the mouth and the tail; and 5 = death.
Determination of Serum CMP-specific (IgG1, IgG2a and
IgG) and Total IgE
Blood samples from mice in the gavage and IP groups
were collected into serum separator tubes (Sarstedt,
Montreal, Quebec, Canada). The serum portion was
separated by centrifugation at 10,000 × g for 5 min at
20°C. Serum samples were then aliquoted into eppen-
dorf tubes and stored at -20°C until being analysed.
CMP-specific serum immunoglobulins, namely IgG1,
IgG2a and IgG as well as total IgE, were detected by
ELISA. Briefly, 96-well plates (Dynatech Laboratories,
Chantilly, VA) were coated with 100 μg/mL of CMP in
0.1 mol/L Na-bicarbonate/carbonate coating buffer (pH
9.6). After overnight incubation at 4°C, plates were
washed 3 times with 150 μl of PBS plus 0.05% Tween-
20 (PBS-T) and blocked with 100 μl of 2% fish gelatine
(Sigma Aldrich, Ontario, Canada) in PBS-T for 1 h at
37°C. Subsequently, the plates were washed 3 times and
100 μl of serially diluted serum samples (started
(a) 
(b) 
Figure 1 Schematic overview of CMP sensitization and challenge protocol in Balb/C mice. (a) Intragastrically sensitized (gavage)
group. Mice were sub-divided into 5 treatments and sensitized intragastrically for 4 weeks as follows (n = 6); CTL-: PBS; CTB: PBS+ CTB (0.25
μg/g BW); CTL+: CMP (1 mg/g BW) + CTB; LGG1: CTL+ mice supplemented with LGG for 5 weeks and LGG2: CTL+ mice supplemented with
LGG for 4 weeks. At d 35, all sensitized mice were intragastrically challenged two times with CMP (30 mg/mouse) at 30 min apart. Two hours
after final challenge, mice were euthanized with CO2 inhalation and blood and spleen samples were collected. (b) Intraperitoneally sensitized
(IP) groups. Mice were sub-divided into 4 treatments and sensitized intraperitoneally for 2 weeks as followed (n = 6); CTL-: PBS; CTL+: CMP (10
mg/mouse); LGG1: CTL+ mice supplemented with LGG for 5 weeks and LGG2: CTL+ mice supplemented with LGG for 4 weeks. At d 35, all
sensitized mice were intragastrically challenged two times with CMP (30 mg/mouse) at 30 min apart. Two hours after final challenge, mice were
euthanized with CO2 inhalation and blood and spleen samples were collected.
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for IgG) were added to the wells and incubated at 37°C
for 90 min. Plates were then washed 3 times, and 100
μL of horseradish peroxidase (HRP) conjugated anti-
mouse antibodies (1:2000 for IgE, IgG1 and IgG2a and
1: 4000 for IgG) were added to each well. The plates
were again incubated at 37°C for another 60 min and
washed 3 times. Then, 100 μl of ABTS were added to
each well and 15 min were allowed for the development
of colorimetric reactions. Absorbance was read at a
wavelength of 405 nm in a microplate reader (Bio-Tek,
Winooski, VT). All analyses were performed in dupli-
cates and the average values were used in the statistical
analysis. Serum titres were calculated by the intersection
of least square regression of A405 versus logarithm of
dilution [22].
Cytokine Measurements from Spleen Lysates
Spleen lysates were prepared as previously described
[23]. Briefly, individual spleens were placed in eppendorf
tubes containing 0.5 ml of lysate buffer. The spleen cells
were lysed and homogenized by sonication for 30 s on
ice. Supernatants were collected after centrifugation at
17,500 g for 10 min at 4°C and stored at -20°C. Interleu-
kin-4 (IL-4) and interferon-gamma (IFN- g) from spleen
lysates were analyzed by commercially available ELISA
kits following the manufacturer’sp r o t o c o l( R & Ds y s -
tems, Minneapolis, MN). Total protein content in spleen
lysates was determined using the detergent compatible
protein assay (Bio-Rad Laboratories Inc., Hercules, CA)
and bovine serum albumin as standard. Cytokine con-
centrations from spleen lysates were expressed as pg/mg
of total protein of spleen.
PCR Identification of Fecal Lactobacillus
For PCR analysis, 100 mg of fecal samples were asepti-
cally weighed, placed in sterile tubes and homogenized
in 1.4 mL stool lysis buffer (QIAamp DNA stool kit;
Qiagen, ON, Canada). Genomic DNA extraction was
performed according to the manufacturer’sp r o t o c o l .
DNA was then amplified using the Crimson taq DNA
Polymerase with Mg-free Buffer, 25 mM MgCl2,1 0m M
dNTP and Crimson Taq DNA Polymerase (New Eng-
land BioLabs, ON, Canada) and Lactobacillus-specific
primers. The primer-set sequences were as described
previously [24]. PCR reactions were performed at 95°C
for 2 min and 95°C for 30 s, followed by 30 cycles of 45
s at 60°C and 68°C for 5 min in an Eppendorf Mastercy-
cler EP Gradient 5341 (Fisher Scientific, ON, Canada).
Finally, the presence of lactobacillus strains was detected
by performing agarose gel electrophoresis 1% (w/v) with
the PCR products and using genomic DNA from pure
L. rhamnosus GG (ATCC53103) as control. The PCR
amplicons were visualized under UV light (260 nm)
followed by a subsequent SafeView nucleic acid staining
(0.5 μg/ml; NBS Biologicals, UK).
Enumeration of Fecal Lactobacilli
Lactobacilli counts were determined from fecal samples
of IP mice at 16 and 30 d. At 12 h prior to sample col-
lection, mice were transferred to new cages which were
lined with moist paper towels instead of the standard
rodent bedding. After fecal sample collection into sterile
microbiology bags, mice were returned into their respec-
tive treatment cages. Sample homogenization, serial
dilutions and culture on bacteria-specific agars were as
previously described [25]. Briefly, fresh fecal pellets were
diluted 10-folds by weight in buffered peptone water,
homogenized, and serially diluted in 0.85% sterile saline
solution. Lactobacilli were anaerobically cultured on
Lactobacilli MRS agar for 24 h at 37°C. Bacterial colo-
n i e sw e r ec o u n t e da tt h ee n do fi n c u b a t i o np e r i o d .
Microbiological analyses were performed in duplicates
and the mean values were used in statistical analyses.
Statistical Analysis
Data were analyzed by a one-way ANOVA using the GLM
procedure of SAS (SAS Institute, 2003) except for the
hypersensitivity scores data which were analyzed using the
Kruskal-Wallis test and SigmaStat software (Systat Soft-
ware Inc., San Jose, CA). Differences among treatment
means were tested using the Scheffe’s multiple comparison
test. P-values ≤ 0.05 were considered significantly different.
Results were presented as mean ± standard deviation. All
microbiological concentrations were subjected to base-10
logarithm transformation before analyses.
Results
Hypersensitivity Responses
Hypersensitivity scores were recorded within an hour
after the final challenge with CMP. In the IP group of
mice, a moderate level of discomfort was observed
among CMP-sensitized mice in the CTL+, LGG1 and
LGG2 treatment groups, while CTL- mice did not show
any visible signs (Figure 2). The average scores for
hypersensitivity symptoms were 2.5 ± 1.05 in CTL+,
1.33 ± 0.82 in LGG1, and 1.167 ± 0.75 in LGG2, respec-
tively. There were no significant differences in hypersen-
sitivity scores among mice in the CTL+, LGG1 and
LGG2 treatment groups. But, in comparison with CTL+
mice, hypersensitivity scores were numerically lowered
in LGG1 and LGG2 mice. In the gavage group, however,
mice did not show any noticeable hypersensitivity
responses (data not shown).
CMP-specific Immunoglobulin Levels in Serum
Serum samples were analyzed by ELISA. In the IP group
of mice, CMP-specific IgG1, IgG2a and IgG levels were
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and LGG2) than non-sensitized (CTL-) mice (Figure 3
and Table 1). Moreover, among CMP-sensitized mice,
CMP-specific IgG2a level was higher in LGG2 than CTL
+ mice. But, CMP-specific IgG1 levels were lower in
both LGG1 and LGG2 in comparison to CTL+ mice.
Total IgE levels were similar across all treatment groups
(Table 1). But, in the gavage group, CMP-specific IgG1
level did not differ between mice in the CTL+, CTL-
and CTB treatments (Table 2).
Cytokine Levels in Spleen Lysates
The IL-4 and IFN-g concentrations from the spleen of
mice in the IP group were not different across treat-
ments (Table 3). In the gavage group of mice, although
similar levels of IL-4 were observed in all the treat-
ments, IFN-g levels were significantly lower in the CTL-
mice when compared to mice in the remaining four
treatment groups (Table 2).
Fecal Counts and PCR Analysis of Lactobacilli
In the IP group of mice, fecal Lactobacilli counts in
LGG1 and LGG2 were similar to those in the CTL- and
CTL+ groups at d 16 (Table 4). But, at d 30, mice in
the LGG2 group had greater Lactobacilli counts than
CTL- mice. However, Lactobacilli counts were similar
between CTL+ and LGG1 mice groups.
PCR analysis was performed on fecal samples to deter-
mine whether probiotic-treated mice excreted higher
lactobacilli. Indeed, higher concentrations of lactobacil-
lus-specific products were detected in fecal samples
from LGG-treated mice than mice in the control groups
(Figure 4). These findings were indicative of higher
levels of the bacteria in the intestinal tract of LGG sup-
plemented mice.
Discussion
CMA is a global health concern that occurs more fre-
quently among children than adults. In infants, high
CMA incidence occurs upon first exposure to CMP, for
example through infant formulas, while the immune sys-
tem is still immature. On the other hand, the intestinal
immune-modulating effects of probiotics [26] have been
shown to reduce the risks of developing allergic diseases
in both mice [14,15,24] and humans [27,28]. The pre-
sent study evaluated whether oral LGG administration
Figure 2 Hypersensitivity scores of intraperitoneally sensitized (IP) mice. Hypersensitivity symptoms were scored one hour after last
challenge with CMP. Each point represents an individual mouse. Values are means, n = 6 per treatment. CTL-: PBS, control mice; CTL+: CMP
sensitized mice; LGG1: CTL+ mice supplemented with LGG for 5 weeks and LGG2: CTL+ mice supplemented with LGG for 4 weeks. Means with
different letters differ, P ≤ 0.05.
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were sensitized with CMP either via the oral (gavage) or
systemic (IP) route. Moreover, to better simulate CMA
in infants, we specifically used 3 week-old newly weaned
Balb/C mice as an animal model and whole CMP as
allergen rather than purified single CMPs.
In the IP group of mice, both LGG1 and LGG2
groups, in comparison with CTL+ mice, may possibly
alleviate allergy as indicated by numerically lower hyper-
sensitivity responses (Figure 2), lower IL-4 levels, and
lower CMP-specific IgG1 but higher IFN-g and CMP-
specific IgG2a levels (Figure 3 and Table 3). Generally,
an increase in Th2 response in mice results in higher
secretions of IL-4, and allergen-specific IgE and IgG1,
whereas increasing the Th1 response leads to higher
IFN-g and IgG2a levels [29]. Therefore, together with
previous in vitro [30] and mice [14,31] studies, our find-
ings suggest that LGG supplementation may alleviate
allergic reactions by supressing Th2-mediated immune
responses. Similarly, allergy reducing effects by probio-
tics have been reported in clinical studies [27,28], in
which LGG or a mixture of probiotics containing LGG
prevented atopic eczema in high risk infants. The anti-
allergic effects of probiotics have also been demon-
strated in ovalbumin-induced asthma [15] and atopic
dermatitis NC/Nga mice models [32]. We also observed
that an additional week of oral LGG administration
between the LGG1 and LGG2 groups of mice did not
significantly alter total Lactobacilli counts, hypersensitiv-
ity scores, and serum concentrations of IL-4, CMP-spe-
cific IgG1 or CMP-specific IgG2a. Therefore, under the
conditions of this study, it appears that greater probiotic
supplementation beyond 4 time points had no major
benefits in alleviating CMA. However, the exact reason
is unknown.
Elevated IL-4, allergen-specific IgE and IgG1 are well
recognized principal immune mediators of IgE-mediated
allergy. Allergen-specific IgE is not easy to be measured
Figure 3 CMP-specific serum IgG1 and IgG2a titres of IP mice. CTL-: PBS; CTL+: CMP (10 mg/mouse); LGG1: CTL+ mice supplemented with
LGG for 5 weeks and LGG2: CTL+ mice supplemented with LGG for 4 weeks. Values are presented as Mean ± standard deviation. Values with
different letters in the same column differ, P ≤ 0.05.
Table 1 Immunoglobulins titres from the sera of IP mice.
Treatments CMP-specific IgG Total IgE*
CTL- 71.67 ± 10.75
b 74.67 ± 28.62
CTL+ 101.0 ± 9.07
a 43.67 ± 14.58
LGG1 102.17 ± 10.64
a 42.67 ± 5.06
LGG2 112.17 ± 8.76
a 79.43 ± 48.21
CTL-: PBS; CTL+: CMP (10 mg/mouse); LGG1: CTL+ mice supplemented with
LGG for 5 weeks and LGG2: CTL+ mice supplemented with LGG for 4 weeks.
Values are presented as Mean ± standard deviation. Values with different
letters in the same column differ, P ≤ 0.05.
*Data were not statistically different, P > 0.05.
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ally present at low levels in the serum and its measure-
ment is more complicated by the serum’sh i g h e rI g G
levels. Moreover, it is reported that both CMP-specific
IgE and IgG have competitive binding ability to similar
epitopes regions of CMP, and that the greater serum
IgG levels significantly reduced the binding capacity of
serum IgE to CMP [33]. But, in the event that specific
IgE is undetectable or non-measurable, IgG1 can be
used as a surrogate maker for IgE if it is accompanied
by increased IL-4 [34,35]. Although we were unable to
detect CMP-specific IgE, our findings about elevated
serum IL-4 together with significantly higher CMP-spe-
cific IgG1 in CTL+ mice in comparison with CTL- mice
indicate that IgE-mediated allergy may have occurred in
CMP-sensitized mice. In agreement with our results,
CMP-specific IgE was also undetectable in other mice
allergy studies [19,36]. It appears that serum concentra-
tions of allergen-specific IgE are highly dependent on
the type of administered allergen. For instance, when
mice were orally sensitized with casein or whey, Schou-
ten et al. [37] successfully measured whey-specific IgE
and IgG1 but could not detect casein-specific IgE. We
presume that CMP-specific IgE responses could have
been reduced in our study considering the fact that
whole CMP contains 20% whey only, but 80% casein. In
addition, we suspect that a direct ELISA method used in
this study might not have been sensitive enough to
detect and measure CMP-specific serum IgE.
Our results about significantly higher hypersensitivity
scores and CMP-specific antibodies titres (IgG1, IgG2a
and IgG) in CMP-sensitized CTL+ mice with compared
to CTL- mice demonstrate that adjuvant-free IP sensiti-
zation successfully stimulated CMP-specific immune
responses (Figure 2, 3 and Table 1). Therefore, an adju-
vant-free systemic sensitization mouse model can well
be adopted to study the allergenicity of low allergen-
containing foods, considering that adjuvant co-adminis-
tration may falsely test non-allergic food products as
allergic [18].
We did not observe visible hypersensitivity symptoms
and different levels of CMP-specific IgG1 and IgG
between CTL+ and CTL- subgroups in orally sensitized
(Gavage) mice (Table 2). We have chosen CTB due to
its non-toxic adjuvant property and it has been used in
food allergy studies [38,39]. However, it seems that
under the conditions of this study, the oral administra-
tion of CMP and CTB mixture was not allergenic to
mice. In addition to the well-known fact that oral sensi-
tization could induce tolerance development, recent
reports indicate that CTB possesses allergy suppressing
rather than stimulating effects in mice through induc-
tion of secretory IgA [40]. Based on our findings and
the above-mentioned report, it seems that CTB may not
be an appropriate oral adjuvant that can successfully
induce CMP-specific allergic responses in Balb/C mice.
Table 3 Cytokines level from spleen lysate of IP mice (pg/
mg of total protein).
Treatments IL-4 (pg/mg)* IFN- g (pg/mg)*
CTL- 15.33 ± 4.51 18.33 ± 3.25
CTL+ 19.3 ± 6.36 21.53 ± 5.69
LGG1 17.35 ± 3.56 26.82 ± 8.02
LGG2 14.47 ± 5.07 26.3 ± 4.69
CTL-: PBS; CTL+: CMP (10 mg/mouse); LGG1: CTL+ mice supplemented with
LGG for 5 weeks and LGG2: CTL+ mice supplemented with LGG for 4 weeks.
Values are presented as Mean ± standard deviation.
*Data were not statistically different, P > 0.05.
Table 4 Fecal counts of total Lactobacilli from IP group at
d 16 and d 30.
Treatments Lactobacilli
d16 d30
CTL- 9.01 ± 0.08 8.70 ± 0.17
b
CTL+ 8.83 ± 0.16 8.89 ± 0.18
ab
LGG1 9.04 ± 0.12 8.86 ± 0.10
ab
LGG2 8.80 ± 0.28 9.03 ± 0.13
a
CTL-: PBS; CTL+: CMP (10 mg/mouse); LGG1: CTL+ mice supplemented with
LGG for 5 weeks and LGG2: CTL+ mice supplemented with LGG for 4 weeks.
Data are presented as the mean log10 colony forming units/g ± standard
deviation of fecal sample. For each bacterium, treatment means with different
letters in the same column differ, P ≤ 0.05.
Table 2 CMP-specific Immunoglobulin titres from the sera and cytokines level from spleen lysate in Gavage group.
Treatments CMP-specific Cytokine (pg/mg)
IgG* IgG1 IL-4* IFN- g
CTL- 68.17 ± 4.14 35.33 ± 11.35
b 9.70 ± 4.64 9.93 ± 0.37
b
CTL+ 68.0 ± 6.08 34.83 ± 5.87
b 10.22 ± 5.65 13.65 ± 1.42
ab
CTB 68.50 ± 3.45 59.50 ± 26.44
b 12.42 ± 6.41 15.52 ± 1.39
ab
LGG1 76.83 ± 13.98 131.33 ± 51.39
a 11.90 ± 4.60 14.47 ± 3.20
ab
LGG2 69.67 ± 5.62 92.17 ± 37.47
ab 8.42 ± 4.66 16.45 ± 2.26
a
CTL-: PBS; CTB: PBS+ CTB (0.25 μg/g BW); CTL+: CMP (10 mg/mouse) + CTB; LGG1: CTL+ mice supplemented with LGG for 5 weeks and LGG2: CTL+ mice
supplemented with LGG for 4 weeks. Values with different letters in the same column differ, P ≤ 0.05. Values are presented as Mean ± standard deviation.
*Data were not statistically different, P > 0.05.
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T oo u rk n o w l e d g e ,w ea r et h ef i r s tt oi n v e s t i g a t et h e
effects of LGG supplementation on CMA in mice that
were sensitized with the whole CMP. We believe that
the adjuvant-free systemic sensitization model may be
particularly useful in the testing of food products with
low allergenicity. LGG administration seems to favour
suppression of Th2 responses such as reduced hypersen-
sitivity scores and lowered serum CMP-specific IgG1
while promoting Th1 responses by causing elevated
IFN-g and CMP-specific IgG2a levels. Although further
experimental and clinical studies are required to eluci-
date the mechanism involved and complete beneficial
effects of LGG, the current study suggests LGG as a
potential preventive tool in the fight against CMA.
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